China Food and Drug Network - November 15th to 16th, the first China Pharmaceutical Valley Future Biological Innovative Drug Conference sponsored by the Daxing Biological Pharmaceutical Industry Base Management Committee of Zhongguancun Science and Technology Park was held in Beijing Daxing. Focusing on the high-quality development of biomedical innovative drugs, the conference gathered more than 300 academics, industry experts and enterprise representatives to conduct in-depth discussions on promoting the deep integration of the development elements of the medical and health industry, and explore effective strategic paths for the future development of biomedical innovative drugs.
Under the background of the rapid development of the global biomedical industry, fully releasing the innovation vitality, accelerating the transformation of scientific research results into practical applications and promoting high-quality development have become the common problems faced by the biomedical field. At the meeting, Jiang Jiandong, an academician of the Chinese Academy of Engineering and president of the Institute of Materia Medica of the Chinese Academy of Medical Sciences, reviewed the development history of innovative drugs in our country and showed the deep heritage of Chinese original drugs. He stressed that innovative drug research and development should pay attention to "systematic thinking", find key targets in complex systems, and play the "head goose" role of key targets in disease intervention to achieve precision treatment.
Professor Du Jie, Beijing Institute of Cardiovascular and Vascular Diseases, took the research and development process of "Sungen Biomedical SGC001 injection" as an example, and described its innovation in depth. He believes that the precise identification of the key molecules of a disease will be a breakthrough in the development of new drugs.
Li Huiyan, a researcher at the Academy of Military Medicine of the Academy of Military Sciences, from the perspective of new immune checkpoint target discovery and antibody drug development, shared 3 possible future innovative drug R&D directions: the regulation of sleep by biological rhythms, the regulation of autoimmune diseases in neuroimmune aspects, and the direction of tumor immunotherapy.
Professor Liu Yuling, Institute of Materia Medica, Chinese Academy of Medical Sciences & Chinese Union Medical College, introduced the development idea of "Mulberry branch total alkaloids" and its indication expansion in the field of metabolic diseases. She said innovative drug development could draw inspiration from ancient Chinese medicine and should be guided by clinical value.
The conference focused on the hot topics of "biological innovation technology", "CXO and innovative drugs to the sea", "biomedical innovation, investment and financing" and other industry topics. Valuable suggestions for the future development of biological innovative drugs were forwarded from the dimensions of technical route of innovative drug R&D, construction of basic R&D platform, opportunities and challenges of clinical research, exploration of new drug routes to sea, investment and financing strategies.
The conference also held the establishment ceremony of the Bioeconomy Committee of the China Asian Economic Development Association and the China Pharmaceutical Valley Biomedical Industry Alliance.
Zhongguancun Science and Technology Park Daxing Biomedical Industry Base (hereinafter referred to as Daxing Pharmaceutical Base), also known as "China's Pharmaceutical Valley", was established in 2002. Up to now, Daxing Pharmaceutical Base has more than 800 enterprises, with 101 platforms in 11 categories, such as public service, CRO, CDMO, common technology, laboratory animals and laboratory testing. It has formed three pillar sectors: vaccine, traditional Chinese medicine and high-end medical devices, and focused on five frontier tracks: cell gene therapy, nucleic acid drugs, medical aesthetics, innovative animal drugs and synthetic biology. (Chang Rui-bo)
Source: China Food and Drug Network
Updated: Nov 18, 2024
